bioRxiv Science⌕ Search

Biology subjects

Barrett, T. J.

Publications and source records attributed to Barrett, T. J..

2 recordsLinked to original sources

Inhibiting LXRα Phosphorylation in Hematopoietic Cells Reduces Inflammation and Attenuates Atherosclerosis and Obesity

Atherosclerosis and obesity share pathological features including inflammation mediated by innate and adaptive immune cells. LXR, a nuclear receptor, plays a central role in the transcription of inflammatory and lipid metabolic genes. LXR is modulated by phosphorylation at serine 196 (LXR pS196), however, the functional consequences of LXR pS196 in hematopoietic cell precursors in atherosclerosis and obesity have not been investigated. To assess the importance of LXR phosphorylation, bone marrow from LXRWT and S196A mice was transplanted into Ldlr-/- mice, which were fed a high fat, high cholesterol diet prior to evaluation of atherosclerosis and obesity. Plaques from S196A mice showed reduced inflammatory monocyte recruitment, lipid accumulation, and macrophage proliferation. Expression profiling of CD68+ cells from S196A mouse plaques revealed downregulation of pro-inflammatory genes and upregulation of mitochondrial genes characteristic of anti-inflammatory macrophages. Furthermore, S196A mice had lower body weight and less visceral adipose tissue; this was associated with transcriptional reprograming of the adipose tissue macrophages and resolution of inflammation resulting in less fat accumulation within adipocytes. Thus, reducing LXR pS196 in hematopoietic cells attenuates atherosclerosis and obesity by reprogramming the transcriptional activity of LXR to an anti-inflammatory phenotype.

molecular biology↗

Phosphorylation of LXRα impacts atherosclerosis regression by modulating monocyte/macrophage trafficking

LXR activation in macrophages enhances regression of atherosclerotic plaques in mice by regulating genes crucial for cholesterol efflux, cell motility and inflammation. Diabetes, however, impairs plaque regression in mice. LXR is phosphorylated at serine 198 (pS198), which affects the expression of genes controlling inflammation, lipid metabolism and cell movement. We hypothesize that LXR function is affected by hyperglycemia through changes in LXR pS198. Indeed, macrophages cultured in diabetes relevant high glucose versus normal glucose display alterations in LXR-dependent gene expression and increased LXR pS198. We therefore examined the consequence of disrupting LXR phosphorylation (S196A in mouse LXR) during regression of atherosclerosis in normal and diabetic mice. We find that phosphorylation deficient LXR S196A reduces macrophage retention in plaques in diabetes, which is predicted to be anti-atherogenic and enhance plaque regression. However, this favorable effect on regression is masked by increased monocyte infiltration in the plaque attributed to leukocytosis in LXR S196A mice. RNA-seq of plaque macrophages from diabetic S196A mice shows increased expression of chemotaxis and decreased expression of cell adhesion genes, consistent with reduced macrophage retention by LXR S196A. Thus, the non-phosphorylated form of LXR precludes macrophage retention in the plaque. Our study provides the first evidence for a physiological role of LXR phosphorylation in modulating atherosclerosis regression. Compounds that prevent LXR phosphorylation or ligands that induce the conformation of non-phosphorylated LXR may selectively enhance macrophage emigration from atherosclerotic plaques.

genetics↗